Normal CBF ~50 mL/100g/min (grey matter 80, white matter 20). CBF is held constant across MAP 60-150 mmHg by autoregulation (myogenic, metabolic, neurogenic, endothelial). Outside this range CBF becomes pressure-passive - the single most exam-relevant concept in neuroanesthesia.

Autoregulation curve: flat plateau 60-150 mmHg -> below 60 pressure-passive ischemia risk -> above 150 forced dilation, vasogenic edema/hemorrhage risk. Curve shifts right in chronic hypertension and is lost/flattened in TBI, severe hypoxia, high volatile concentrations.

• Endothelial tight junctions (claudin-5, occludin, ZO-1) - principal anatomical basis of BBB
• Basement membrane - continuous, non-fenestrated
• Pericytes - regulate permeability and angiogenesis
• Astrocytic end-feet - ensheath >99% of capillary surface
• Efflux transporters (P-glycoprotein) exclude lipophilic xenobiotics

Functional: permits small lipophilic molecules by diffusion; excludes ionized/polar molecules unless actively transported (GLUT-1, LAT-1).

Normal ICP 5-15 mmHg (supine adult). CPP = MAP - ICP (or -CVP if higher). Target CPP in TBI: 60-70 mmHg (BTF).

Fiberoptic catheter retrogradely placed in the internal jugular vein (dominant side) with tip at the jugular bulb samples global cerebral venous oxygen saturation.

Limitation: global not regional - focal ischemia can be masked. Requires frequent co-oximetry calibration. Complements PbtO2 for regional data.

Draw the autoregulation curve with numeric limits (60-150 mmHg). State Monro-Kellie quantitatively (80:10:10). For SjO2 always mention it is a global, not regional, measure.

Sugammadex is a modified gamma-cyclodextrin that reverses aminosteroid NMBs (rocuronium > vecuronium) by direct molecular encapsulation - not enzyme inhibition - allowing reversal of any depth of block, including immediate post-induction rescue.

Large margin of safety - only 70-80% receptor occupancy needed to block transmission; ~75% must be blocked before twitch height visibly falls on TOF.

• Distribution: Vd ~11-14 L
• Metabolism: sugammadex itself is NOT metabolized, pharmacologically inert once bound
• Elimination: free sugammadex and sugammadex-rocuronium complex eliminated almost entirely unchanged renally (>90% in 24h); t1/2 ~2h
• Mechanism: encapsulation creates a concentration gradient drawing rocuronium from NMJ back to plasma (""Le Chatelier"")

Endpoint of adequate reversal: quantitative TOF ratio >=0.9 on objective monitoring - tactile/visual assessment is unreliable above TOF 0.4.

• Anaphylaxis: ~0.039-0.3% incidence (dose-dependent, higher with 16 mg/kg); NAP6 (UK) identified sugammadex as a significant trigger, can occur on first exposure
• Cardiac: generally stable; bradycardia (including rare severe cases) - FDA warning to keep atropine available
• Coagulation: mild transient aPTT/PT prolongation
• Hormonal: transiently binds progesterone - advise additional contraception for 7 days

Contrast encapsulation vs AChE inhibition explicitly. Quote the three dosing scenarios (2/4/16 mg/kg) tied to TOF/PTC criteria, and mention NAP6 for anaphylaxis.

A variable-bypass vaporizer splits fresh gas flow between a bypass channel (never touches liquid) and a vaporizing chamber (saturated with agent vapor), recombining so the output equals the dial-set % regardless of FGF, within the design range (0.2-15 L/min).

FGF enters -> splits at splitting valve: (1) bypass flow (majority) and (2) vaporizing chamber flow (saturated over wicks) -> streams recombine downstream -> dial controls splitting ratio.

• Wick system increases surface area for evaporation
• Agent-specific keyed filling systems (Tec-fill, Saf-T-fill) prevent cross-filling
• Concentration-calibrated (not flow-calibrated)
• Located outside the circle system (VOC), interlocked against simultaneous use of >1 vaporizer

As liquid vaporizes it absorbs latent heat -> chamber cools -> SVP falls -> output would decrease. Compensation:

Flow compensation: modern vaporizers use flow-dependent, non-linear splitting ratios to maintain accurate output across 0.2-15 L/min.

• Tilting/overturning: liquid can spill into bypass channel -> unpredictable concentrated bolus
• Overfilling beyond max mark: same hazard
• Underfilling: inadequate wick saturation -> falsely low output, awareness risk
• Post-tilt protocol: take out of service, flush at high FGF/high setting with chamber isolated before reuse
• Desflurane exception: needs an electrically heated, pressurized vaporizer (Tec 6), not simple variable-bypass

Explain temperature compensation mechanistically (bimetallic strip + thermal mass). Tie pumping effect explicitly to IPPV and differential gas compressibility.

Mapleson systems are valveless (semi-open) circuits classified A-F by relative position of the fresh gas inlet, reservoir bag, and APL valve. Efficiency at preventing rebreathing differs dramatically between spontaneous and controlled ventilation.

Mnemonic: efficiency for spontaneous ventilation A > DFE > CB. For controlled ventilation: DFE > BC > A (reverse order).

Why preferred in pediatrics: lightweight, minimal apparatus dead space, very low resistance, direct feel/observation of compliance.

State the mnemonic ranking explicitly and explain the mechanism for Mapleson A. Always volunteer the Bain inner-tube disconnection hazard.

Dexmedetomidine is a highly selective alpha2-adrenergic agonist (alpha2:alpha1 ~1620:1) that produces sedation by hijacking the brain's natural sleep pathway (locus coeruleus -> VLPO) rather than acting on GABA receptors - explaining its ""cooperative/arousable sedation"" profile and lack of significant respiratory depression.

• Target: alpha2-adrenoceptors (alpha2A/2B/2C), Gi-coupled, lower cAMP
• alpha2A: sedation, analgesia, sympatholysis (locus coeruleus, spinal cord)
• alpha2B: initial vasoconstrictive hypertensive response, shivering suppression
• alpha2C: cognitive/sensory modulation, startle response
• Presynaptic: inhibits NE release; Postsynaptic: hyperpolarizes locus coeruleus neurons

Binds alpha2A in locus coeruleus -> hyperpolarization, lower NE release -> disinhibits ventrolateral preoptic nucleus (VLPO) -> VLPO releases GABA/galanin -> suppresses arousal centers -> mimics natural non-REM (stage 2) sleep. This differs fundamentally from GABAergic agents (propofol/benzodiazepines) which directly potentiate GABA-A receptors - explaining easy arousability. Analgesic mechanism: dorsal horn alpha2 agonism inhibits substance P, opioid-receptor-independent.

Hepatic impairment significantly prolongs clearance (dose reduction needed); renal impairment has minimal effect on parent drug.

Bradycardia common (caution with beta-blockers/heart block). Reduces MAC and blunts laryngoscopy response. Does NOT cause significant myocardial depression.

• Analgesic/opioid-sparing
• Anti-shivering (alpha2B, resets hypothalamic threshold)
• Reduces emergence delirium and PACU agitation
• Diuresis (inhibits ADH)
• No effect on seizure threshold - useful during neurophysiological monitoring

Name the locus coeruleus -> VLPO pathway explicitly. Describe the biphasic CV response with receptor basis. State respiratory drive preservation and tie to awake fiberoptic intubation.

The supraclavicular approach blocks the plexus at the trunks/divisions - the most compact point, lateral and superficial to the subclavian artery just above the first rib - the ""spinal of the arm"": dense, rapid anesthesia of the entire upper limb from one injection.

Roots (C5-T1) emerge between scalenus anterior/medius -> Trunks (upper C5-6, middle C7, lower C8-T1) at interscalene groove -> cross first rib, split into Divisions behind clavicle -> reorganize into Cords (lateral/posterior/medial) in axilla -> Terminal Branches. Mnemonic: Roots, Trunks, Divisions, Cords, Branches.

• Trunks lie superior/lateral/posterior to subclavian artery - ""bunch of grapes""/""traffic light"" pattern
• Subclavian artery anterior to first rib and pleura/lung apex
• First rib and pleura lie deep/medial to artery - basis of historical pneumothorax risk
• Suprascapular nerve often already branched off
• Phrenic nerve on anterior scalenus anterior, medial/anterior to plexus

• Position: supine, head turned away, arm adducted
• Probe: 10-15 MHz linear, supraclavicular fossa, angled caudally
• Identify subclavian artery, then plexus cluster, then first rib/pleura (confirm lung sliding)
• Needle: in-plane, lateral to medial (preferred)
• Target the corner pocket first for lower trunk/ulnar coverage
• Inject incrementally 3-5 mL aliquots with intermittent aspiration, watch halo sign
• Volume: 20-30 mL (0.5% ropivacaine or 0.375-0.5% bupivacaine +/- dexamethasone)
• Confirm spread around all trunk components before withdrawing

Draw/describe the ""bunch of grapes"" appearance relative to the subclavian artery. Mention the corner-pocket strategy and the ~50% phrenic nerve incidence figure.

HPV is a unique, intrinsic, locally-mediated pulmonary vascular reflex - opposite of systemic circulation where hypoxia causes vasodilation. By diverting flow away from poorly-ventilated alveoli, HPV optimizes V/Q matching and is the single most important mechanism limiting hypoxemia during OLV.

Alveolar hypoxia (primary trigger) -> sensed by pulmonary vascular smooth muscle cells themselves -> inhibition of Kv channels -> depolarization -> Ca2+ influx/release -> smooth muscle contraction -> vasoconstriction of small pulmonary arterioles -> blood diverted to better-ventilated regions.

• Site: pre-capillary arterioles (200-500 um), not larger conducting arteries
• Biphasic: immediate phase (minutes) + sustained phase (hours)
• Regional/local, functions independently in each segment - persists in denervated/transplanted lungs
• Can reduce flow to a hypoxic region by up to 50%

• Hypoxemia is the principal concern - non-ventilated lung still gets ~20-30% CO as shunt
• V/Q mismatch: non-dependent lung becomes a pure shunt unit
• Time course: HPV reduces non-ventilated lung flow from ~40% to ~20-25% within 20-30 minutes

State HPV is local/intrinsic (persists in denervated lungs). List 4-5 blunting factors with mechanism and connect back to OLV hypoxemia troubleshooting.

LAST occurs because LAs block voltage-gated Na+ channels non-selectively - at sufficient systemic concentration they block CNS and cardiac Na+ channels. Bupivacaine is disproportionately cardiotoxic due to ""fast-in, slow-out"" kinetics; CNS toxicity classically precedes cardiac toxicity except with bupivacaine.

• Primary: Na+ channel blockade in excitable tissue at toxic systemic concentrations
• CNS: preferentially blocks inhibitory interneurons first -> excitatory phase -> then global depression
• Cardiac: slows phase 0 depolarization -> conduction slowing -> re-entrant arrhythmias; bupivacaine also inhibits mitochondrial fatty acid metabolism
• ""Fast-in, slow-out"" (bupivacaine): rapid binding during systole, slow dissociation during diastole -> cumulative use-dependent block at normal heart rates -> disproportionate cardiotoxicity

Bupivacaine cardiac arrest is classically refractory to standard ACLS - lipid emulsion is a specific antidote; prolonged resuscitation (up to an hour+) may succeed.

Concurrent measures: stop injecting LA, call for help, get lipid kit; 100% O2; benzodiazepines for seizures (avoid propofol if unstable); reduce initial epinephrine to <=1 mcg/kg, avoid vasopressin/CCBs/beta-blockers, amiodarone preferred for VT; prepare for prolonged resuscitation (>1h), consider CPB early; monitor 4-6h post-event (2h if CNS-only).

Quote the lipid protocol exactly (1.5 mL/kg bolus, 0.25 mL/kg/min infusion, max 12 mL/kg). Mention 40-60% atypical presentations and reduced epinephrine dosing.

This patient combines two independent high-risk factors: severe systolic heart failure (EF 25%) requiring meticulous hemodynamic management, and a CIED requiring EMI mitigation, especially with monopolar electrocautery near the upper abdomen. Manage both simultaneously.

Cardiac optimization: assess NYHA class/recent decompensation; review recent echo; continue beta-blockers, hold ACE-I/ARB morning of surgery; correct K+/Mg2+; ECG, BNP/troponin baseline; involve high-risk team early given urgent status.

Anesthetic technique: GA typically required (open surgery). Goal: hemodynamic stability, avoid myocardial depression - slow titrated induction with etomidate or careful low-dose propofol, high-dose opioid. Avoid ketamine if active ischemia a concern. Maintenance: low-dose volatile + opioid, or careful TIVA. Avoid both tachycardia/excess afterload and excessive bradycardia/hypotension.

• ICU/HDU admission for continuous monitoring
• Device re-interrogation by cardiology - confirm function, restore original settings
• Judicious fluid management, inotropic support if needed (dobutamine/milrinone)
• Multimodal analgesia (rectus sheath/TAP blocks) to minimize opioid/sympathetic swings
• Resume cardiac medications as tolerated; monitor for arrhythmia/ischemia/decompensation

Structure the answer around the two parallel risk domains (cardiomyopathy + CIED/EMI). State the surgical-site rule (above umbilicus = higher EMI risk) and mention external pacing/defib availability.

BCIS results from embolic phenomena (fat, marrow, cement, air forced into venous circulation during pressurization/insertion) plus the direct vasoactive/cardiodepressant effects of circulating methylmethacrylate monomer - spectrum from transient hypoxemia to catastrophic collapse, most dramatic at cementing/insertion.

Reaming + cement pressurization -> marrow fat, debris, air, monomer forced into venous sinusoids -> embolization to lungs -> (1) mechanical obstruction -> raised PVR -> acute RV strain -> (2) complement/histamine release -> further vasoconstriction/bronchoconstriction -> (3) monomer -> peripheral vasodilation + direct myocardial depression -> combined hypoxemia + hypotension +/- arrest.

Highest-risk moments: femoral canal reaming/broaching, cement insertion, prosthesis insertion, joint reduction.

1. Immediate recognition via temporal correlation with cementation

2. FiO2 100% immediately

3. IV fluid bolus + vasopressors (phenylephrine/noradrenaline) for hypotension; inotropes if RV dysfunction dominates

4. Communicate with surgeon, may pause the step

5. Treat as acute PE/RV strain physiologically; TEE if available

6. Full ACLS/CPR if Grade 3; prolonged resuscitation may be needed

7. Postoperative ICU monitoring, serial reassessment

State Donaldson's grading with exact numeric thresholds. Identify femoral canal venting and lavage as the two most effective preventive interventions; distinguish prevention from treatment clearly.

Severe thrombocytopenia (45,000/mm3) raises concern for spinal/epidural hematoma with neuraxial technique, while GA carries its own severe risks in pre-eclampsia (exaggerated pressor response, difficult airway, magnesium-NMB interaction). Fetal distress adds time pressure.

Decision in this case: with platelets at 45,000, most protocols favor GA due to unacceptable hematoma risk, despite GA's own risks - unless recent reliable coagulation profile supports individualized regional decision.

Target SBP <160, DBP <110 mmHg; avoid overly aggressive correction to preserve uteroplacental perfusion.

Treatment of toxicity: stop infusion, calcium gluconate 1g (10mL 10%) IV antidote, supportive ventilation.

PPH: oxytocin infusion first-line (slow, avoid bolus hypotension); avoid ergometrine (hypertensive effect); carboprost with caution; anticipate platelet transfusion need; escalate atony management per standard ladder.

Explicitly justify the GA-vs-regional choice using the given platelet count. Quote the magnesium toxicity staged levels with numbers and the calcium gluconate dose exactly.

Pheochromocytoma anesthesia swings from hypertensive crisis (induction, tumor handling, pneumoperitoneum) to potentially severe hypotension after venous ligation removes the catecholamine source. Adequate preoperative alpha-blockade is the single most important determinant of stability.

Beta-blockade added only AFTER adequate alpha-blockade (never start beta first - unopposed alpha stimulation -> crisis). Liberal volume/salt expansion preoperatively blunts post-excision hypotension.

High-risk triggers: laryngoscopy/intubation, pneumoperitoneum insufflation, direct tumor manipulation (highest risk), positioning changes.

Invasive arterial line before induction; central venous access; continuous ECG; communicate with surgeon before high-risk manipulation.

1. Anticipate - advance warning from surgeon, vasopressors drawn up

2. Volume loading before/during this phase

3. Stop/reduce vasodilator infusions immediately

4. Vasopressors: noradrenaline/phenylephrine first-line; vasopressin if refractory

5. Hydrocortisone if bilateral adrenalectomy

6. Monitor glucose closely (rebound hyperinsulinemia -> hypoglycemia)

7. Continue ICU monitoring 24-48h postoperatively

Quote Roizen's criteria by number - the single most commonly tested fact here. Structure the answer around the three hemodynamic phases and always mention post-excision hypoglycemia.

Pheochromocytoma anesthesia swings from hypertensive crisis (induction, tumor handling, pneumoperitoneum) to potentially severe hypotension after venous ligation removes the catecholamine source. Adequate preoperative alpha-blockade is the single most important determinant of stability.

Beta-blockade added only AFTER adequate alpha-blockade (never start beta first - unopposed alpha stimulation -> crisis). Liberal volume/salt expansion preoperatively blunts post-excision hypotension.

High-risk triggers: laryngoscopy/intubation, pneumoperitoneum insufflation, direct tumor manipulation (highest risk), positioning changes.

Invasive arterial line before induction; central venous access; continuous ECG; communicate with surgeon before high-risk manipulation.

1. Anticipate - advance warning from surgeon, vasopressors drawn up

2. Volume loading before/during this phase

3. Stop/reduce vasodilator infusions immediately

4. Vasopressors: noradrenaline/phenylephrine first-line; vasopressin if refractory

5. Hydrocortisone if bilateral adrenalectomy

6. Monitor glucose closely (rebound hyperinsulinemia -> hypoglycemia)

7. Continue ICU monitoring 24-48h postoperatively

Quote Roizen's criteria by number - the single most commonly tested fact here. Structure the answer around the three hemodynamic phases and always mention post-excision hypoglycemia.

Pediatric FB aspiration anesthesia is unique because the surgeon and anesthesiologist share the airway - the goal is to maintain spontaneous ventilation wherever possible, avoiding positive-pressure ventilation that could push the object distally or cause ball-valve air-trapping/pneumothorax.

1. Inhalational induction with sevoflurane in 100% O2

2. Avoid muscle relaxants initially

3. Deepen with additional volatile +/- topical lidocaine (<=4-5 mg/kg max)

4. Shared airway technique via rigid bronchoscope side-port

5. TIVA (propofol +/- remifentanil) increasingly favored as alternative to volatile through an open scope

6. Continuous communication with surgeon, brief interruptions for oxygenation between attempts

7. Be prepared to advance the object past carina to one side if complete obstruction threatens

SpO2/ETCO2 (often intermittent given open airway); watch for sudden desaturation, laryngospasm, or pneumothorax; have chest drain kit ready.

Postop: watch for post-obstructive pulmonary edema, laryngeal/subglottic edema (nebulized adrenaline/dexamethasone if stridor), residual fragments, aspiration pneumonitis.

Explain WHY spontaneous ventilation is preserved (ball-valve mechanism) rather than just stating it as a rule. Mention TIVA as a modern alternative to volatile through an open bronchoscope.

The sitting position offers excellent surgical access but creates a unique hazard: non-collapsible dural venous sinuses held open by bone/fibrous attachments sit at the highest point of the field, often above the right atrium - creating a negative pressure gradient that can entrain air directly into venous circulation.

Preop: echocardiography for PFO (~25-30% prevalence - if present, sitting position often avoided); assess cardiovascular reserve; cervical spine assessment.

Positioning: gradual staged elevation; lower extremity compression; minimum 2-finger chin-to-sternum distance; pad all pressure points.

Open dural sinus/large vein above right atrium -> held open by surrounding bone (non-collapsible) -> negative pressure gradient -> atmospheric air entrained -> travels to right heart -> (1) air lock/mechanical outflow obstruction, (2) diffuse pulmonary microvascular obstruction, (3) if PFO present, paradoxical air embolism -> stroke/coronary air embolism.

Incidence reported as high as 25-40% with sensitive monitoring, though most episodes are small-volume.

Quote the sensitivity-ranked detection list with precordial Doppler at the top. Explain WHY dural sinuses are vulnerable (non-collapsible, held open by bone). Name Durant's maneuver specifically.

RALP combines two independently stressful insults that compound each other: pneumoperitoneum (raised intra-abdominal pressure, CO2 absorption) and steep Trendelenburg (30-45 deg head-down for hours) - causing cephalad fluid shift, raised ICP/IOP, reduced pulmonary compliance, and altered cerebral autoregulation.

• Increased IOP from elevated episcleral venous pressure and choroidal congestion, worsens with duration
• Postoperative visual loss (POVL) - rare but devastating, mainly ischemic optic neuropathy from prolonged positioning, venous congestion, relative hypotension, anemia, prolonged duration
• Conjunctival/periorbital edema (chemosis) - usually self-limiting
• Prevention: minimize angle/duration, avoid excessive crystalloid, maintain hemoglobin, careful eye protection/padding

• Reduced FRC/compliance from cephalad viscera and diaphragm displacement
• Increased peak/plateau pressures - pressure-controlled ventilation often preferred
• Atelectasis in dependent regions - recruitment + PEEP balanced against hemodynamic/ICP effects
• Risk of endobronchial intubation from cephalad mediastinal shift - re-auscultate after final positioning
• CO2 absorption requires increased minute ventilation; rare capnothorax/subcutaneous emphysema

• Cerebral autoregulation generally preserved but hypercapnia (vasodilator) + venous congestion can push CBV/ICP higher
• Airway/facial edema may warrant cuff-leak test or delayed extubation after prolonged cases
• Relative contraindications: pre-existing raised ICP, cerebrovascular disease, severe cardiopulmonary disease, glaucoma

Controlled pressure-limited ventilation with titrated PEEP; invasive arterial monitoring for prolonged/high-risk cases; judicious/restrictive fluid management; maintain hemoglobin; meticulous eye protection; minimize total steep time; gradual return to supine with hemodynamic monitoring.

Structure the answer explicitly across ocular, respiratory, and cerebrovascular systems as demanded. Name ischemic optic neuropathy specifically and mention the role of fluid restriction.

The ARDS lung is functionally a ""baby lung"" - only a fraction of normal-sized lung tissue remains aerated/compliant. Ventilating this small volume with conventional tidal volumes causes VILI via volutrauma, barotrauma, atelectrauma, and biotrauma - driving low tidal volume, adequate PEEP, and prone positioning strategy.

• ARDSNet target: Vt 4-8 mL/kg (commonly start 6 mL/kg) of predicted/ideal body weight (PBW), NOT actual body weight
• Why PBW: lung size correlates with height/sex, not fat/edema-related weight
• IBW formula: Male = 50 + 0.91x(height cm - 152.4); Female = 45.5 + 0.91x(height cm - 152.4)
• Plateau pressure target <30 cmH2O (some evidence supports <=27-28 when feasible)
• Permissive hypercapnia accepted (pH tolerated to 7.20-7.25) - caution with raised ICP/RV dysfunction

PEEP: maintains recruitment, prevents atelectrauma. Higher PEEP favored in moderate-severe ARDS (P/F<200) per patient-level meta-analyses. Titration via ARDSNet tables, best-compliance, esophageal pressure, or decremental trials.

NMB: early short-course (~48h) infusion considered in P/F<150. ACURASYS (2010) suggested mortality benefit; ROSE (2019) found no difference with light sedation + as-needed NMB - current practice is individualized, not routine.

Indications: P/F<150 on PEEP>=5 and FiO2>=0.6 despite optimization (PROSEVA criteria). Initiate early (24-48h), sessions >=16 h/day.

Contraindications: unstable spine fracture, raised ICP, recent open abdomen, hemodynamic instability, late pregnancy.

Write out the exact IBW formula. Mention driving pressure with the Amato 2015 reference and >15 cmH2O threshold. Show awareness of the ACURASYS vs ROSE NMB evidence evolution.

Modern MTP has shifted from ""1:1:1 ratio-driven"" empiric resuscitation toward viscoelastic-guided, goal-directed component therapy, recognizing trauma-induced coagulopathy is complex and multifactorial rather than simply dilutional.

Activation scores: ABC score (penetrating mechanism, positive FAST, SBP<=90, HR>=120; score>=2 predicts need). Shock Index (HR/SBP>1.0). Clinical gestalt should prompt early activation regardless of formal score.

TXA: 1g IV loading over 10 min + 1g infusion over 8h, within 3 hours of injury (CRASH-2). Benefit is time-dependent - beyond 3h, no benefit/possible harm.

PCC: concentrated factors II,VII,IX,X - rapid VKA reversal; faster/lower volume than FFP; caution re: thrombotic risk.

Quote the CRASH-2 TXA dosing/timing exactly (1g bolus + 1g over 8h, within 3h). Give a clear TACO vs TRALI comparison. Mention ""fibrinolysis shutdown"" as a distinct phenotype.

Brain death is the complete and irreversible cessation of all brain and brainstem function, legally equivalent to death under India's THOA (1994, amended 2011/2014). Once declared, focus shifts entirely to active multiorgan donor optimization.

Preconditions: known cause of irreversible brain injury; exclusion of reversible causes (hypothermia, severe metabolic/endocrine disturbance, drug/NMB effect, profound uncorrected hypotension).

Explicitly state the THOA requirement of two examinations by a panel of four doctors, separated by the standard interval, none from the transplant team. Frame donor management around the autonomic-storm-to-hormonal-collapse narrative.

POCUS protocols transform bedside ultrasound into a structured diagnostic pathway - RUSH systematically interrogates the ""pump, tank, and pipes"" to rapidly differentiate shock etiology; BLUE uses characteristic named artifact patterns to diagnose acute respiratory failure within minutes, without moving the patient.

Real-time, repeatable, bedside - avoids transporting an unstable patient. Reduces diagnostic time from hours to minutes. Guides therapeutic decisions (fluid responsiveness, tamponade/pneumothorax, line placement). Complements, does not replace, clinical exam/formal imaging.

BLUE profiles: A-profile+DVT = PE; B-profile bilateral = pulmonary edema/ARDS; asymmetric B/consolidation = pneumonia; absent sliding + lung point = pneumothorax; PLAPS profile = basal pneumonia.

RUSH and BLUE can be combined/sequenced for undifferentiated hypotension + respiratory distress. Serial exams track response to therapy. Limitations: operator-dependence, body habitus, training requirement; cannot fully replace comprehensive echo.

Memorize and write ""pump, tank, pipes"" explicitly. Name at least A-profile/B-profile/lung point findings with their diagnoses. Mention POCUS avoids transporting an unstable patient.

Cardiac surgery-associated AKI is multifactorial - CPB-related hemodilution/inflammation, non-pulsatile flow/hypoperfusion, hemolysis-related nephrotoxicity, and embolic phenomena. Even mild AKI (KDIGO Stage 1) is independently associated with increased mortality.

Diagnosis requires only ONE criterion; stage by whichever indicates more severe injury. Risk factors: pre-existing CKD/diabetes/age, prolonged CPB/cross-clamp time, hemodilution, hemolysis, non-pulsatile flow, embolic phenomena, nephrotoxin exposure, low cardiac output.

Serial creatinine trend, hourly urine output, urinalysis/microscopy, fractional excretion, novel biomarkers (NGAL, cystatin C, TIMP-2xIGFBP7), renal ultrasound if needed, hemodynamic/echo assessment.

Current consensus (post-STARRT-AKI): a ""watchful-waiting"" strategy - initiate based on absolute indications or clear deterioration rather than routine early initiation. CRRT (vs IHD) preferred in hemodynamically unstable patients due to gentler, continuous fluid/solute removal.

Write out the full KDIGO staging table with exact ratios/thresholds. Quote the AEIOU mnemonic. Name the STARRT-AKI trial and its no-benefit conclusion explicitly.

Modern anesthesia workstations are engineered around multiple, layered, independent safety systems - each addressing a specific historically-documented failure mode. The shift from purely mechanical/pneumatic safeguards to integrated electronic monitoring is the most significant recent advance.

• Agent-specific keyed filling systems prevent mis-filling
• Vaporizer interlock system prevents simultaneous engagement of >1 vaporizer
• Inline gas analyzers identify agent and cross-check dial setting

Explicitly contrast mechanical vs electronic hypoxic guard mechanisms. Explain fresh gas decoupling with a clear ""why it matters"" framing rather than just naming it.

All processed-EEG depth-of-anesthesia monitors are proprietary, manufacturer-derived statistical indices built from raw frontal EEG - not direct measures of consciousness - each using different mathematical approaches, all sharing vulnerability to artifact and agent-specific calibration issues.

State Entropy (SE, 0.8-32 Hz, cortical only) vs Response Entropy (RE, 0.8-47 Hz, includes frontal EMG). A widening RE-SE gap indicates EMG/muscle activity - suggesting inadequate analgesia/light anesthesia even if SE looks adequate.

Most beneficial as part of a protocol-driven approach in high-risk populations: TIVA-based anesthesia, neuromuscular-blocked patients, cardiac/trauma surgery, prior awareness history. Should be considered an adjunct to, not a replacement for, sound clinical judgment and end-tidal agent monitoring.

Name the specific mathematical basis distinguishing each monitor. The RE-SE gap and its meaning is frequently tested. Cite B-Unaware/B-Aware/BAG-RECALL to show these monitors reduce but do not eliminate awareness.

The defining advance separating second-generation from first-generation SADs is a dedicated gastric (drain) channel - allowing separation of respiratory and alimentary tracts, addressing the primary safety limitation of first-generation devices: aspiration vulnerability.

• Reduced aspiration risk via dedicated gastric channel (passive drainage + active gastric tube placement)
• Improved seal reduces gastric insufflation during PPV
• Gastric tube test confirms correct placement
• Integrated bite block reduces device damage from biting
• No SAD (any generation) matches a cuffed ETT's aspiration protection - remains contraindicated in high-risk patients (full stomach, severe GERD, bowel obstruction)

State the defining structural difference (gastric channel) immediately. Quote specific OLP numbers for 2-3 named devices. Conclude that even second-generation SADs don't replace a cuffed ETT in high-risk patients.

TCI systems use a computer-controlled pump running a population pharmacokinetic model to achieve/maintain a clinician-set target concentration. Marsh and Schnider differ in derived population and covariates, producing clinically meaningful dosing differences in non-average patients.

Clinician sets a target (plasma or effect-site) -> a 3-compartment PK model (central + 2 peripheral) with population rate constants -> pump calculates/adjusts infusion in real time.

Plasma-targeting: achieves plasma concentration quickly, may overshoot effect-site before equilibration.

Effect-site targeting: uses ke0 to drive faster brain equilibration, more closely tracking clinically relevant concentration.

State explicitly: Marsh uses total body weight with no age adjustment; Schnider uses lean body mass plus age with a fixed central compartment volume. Connect to a practical elderly/obese scenario.

GDFT is built on the insight that only about 50% of hemodynamically unstable patients are actually fluid-responsive. Dynamic parameters, exploiting heart-lung interactions during PPV, are far superior to static parameters at predicting responders.

Traditional fixed-volume regimens caused under- or over-resuscitation. GDFT titrates fluid/vasoactive therapy to real-time hemodynamic data. Evidence shows reduced complications (SSI, anastomotic leak, ileus, AKI) and reduced LOS, especially within ERAS protocols and in high-risk populations.

Algorithm: give a bolus (~250 mL over 5-10 min) only when a validated trigger is present -> reassess SV -> if SV rises >=10-15%, responder, may repeat; if not, withhold and consider vasopressor/inotrope.

State explicitly that only ~50% of unstable patients are fluid-responsive - this justifies GDFT entirely. List the full PPV/SVV validity prerequisites and name passive leg raise as the solution when unmet.

All three sub-topics represent areas of major recent practice shift based on landmark RCT evidence (TTM2 reshaping post-arrest temperature targets) or rapid technology adoption (HFNO/THRIVE transforming pre-oxygenation, AI-driven closed-loop delivery as the emerging frontier).

Current practice: active fever prevention (target <=37.5C) is now the recommended minimum for all comatose post-arrest patients; targeted hypothermia may still be individualized. Duration >=24h if chosen, gradual rewarming 0.25-0.5C/hr. Watch shivering, coagulopathy, electrolyte shifts.

Delivers heated humidified O2 up to 60-70 L/min at titratable FiO2 to 1.0, generates modest PEEP-like effect (1-5 cmH2O), washes out anatomical dead space.

Limitation: maintains oxygenation but not ventilation/CO2 clearance - hypercapnia develops with prolonged apnea; not a substitute for definitive airway management.

Uses continuous feedback (e.g. BIS) with an automated control algorithm adjusting propofol/remifentanil infusion in real time - analogous to autopilot.

Lead each part with the single most current named evidence - TTM2 trial for (a), THRIVE concept for (b), PID-vs-AI/ML distinction for (c). Precision and terminology matter more than length for short notes.